Effects of nasal high-flow therapy on heart function in pulmonary hypertension patients
Physiological Evaluation of the Hemodynamic Effects of Nasal High Flow in Patients Being Explored by Right Heart Catheterisation and Echocardiography for Suspected or Followed Precapillary Pulmonary Hypertension
This study tests if using nasal high-flow therapy can improve heart function in patients with suspected pulmonary hypertension.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | ADIR Association Academic / other |
| Locations | 1 site (Rouen) |
| Trial ID | NCT06079151 on ClinicalTrials.gov |
What this trial studies
This study investigates the hemodynamic effects of nasal high-flow therapy in patients suspected of having precapillary pulmonary hypertension. It aims to measure changes in cardiac output during right heart catheterization and echocardiography, hypothesizing that nasal high-flow will enhance cardiac output. The study will utilize echocardiography to assess the sensitivity of detecting cardiovascular changes resulting from this therapy.
Who should consider this trial
Good fit: Ideal candidates are patients undergoing right heart catheterization for suspected or monitored precapillary pulmonary hypertension.
Not a fit: Patients requiring more than 21% oxygen during the procedure or those with severe cardiac conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the management of pulmonary hypertension by enhancing cardiac function.
How similar studies have performed: While similar studies have explored high-flow therapies, this specific approach in the context of pulmonary hypertension is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up. Exclusion Criteria: * necessity of FiO2 \>21% during right heart catheterization * intracardiac shunt * grade 4 tricuspid insufficiency * complete arrhythmia due to atrial fibrillation * Pregnant or breastfeeding women or women of childbearing age without an effective method of contraception * protected adult patient (tutorship or curatorship) * patient deprived of liberty by court or administrative decision * refusal of patient participation or consent * patient for whom the measurement of pulmonary arterial pressures during right heart catheterization is impossible * patient for whom, during the etiological assessment of pulmonary hypertension, the diagnosis of precapillary pulmonary hypertension cannot be confirmed and classified in groups 1, 3 or 4.
Where this trial is running
Rouen
- ROUEN university hospital — Rouen, France (Recruiting)
Study contacts
- Principal investigator: Elise ARTAUD-MACARI, MD — ADIR Association
- Study coordinator: Elise ARTAUD-MACARI, MD
- Email: elise.artaud-macari@chu-rouen.fr
- Phone: +33 2 32 88 59 92
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.